Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog With Weekly Dosing Potential

VRB-103, a potential once-weekly, selective oral amylin analog, is being evaluated in a Phase 1 study as both a monotherapy and in combination with VRB-101 (oral ecnoglutide), a once-weekly oral GLP-1 analog Once-weekly oral dosing of both VRB-103 and VRB-101 enabled by clinically validated, potential best-in-class peptide delivery platform VRB-103 is the first known, once-weekly oral amylin analog currently in clinical development Initial data currently anticipated by the end of 2026